Institutional members access full text with Ovid®

Share this article on:

Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant.

Herring, W. Joseph MD, PhD; Ge, Joy Y. PhD; Jackson, Saheeda BS; Assaid, Christopher PhD; Connor, Kathryn M. MD, MHS; Michelson, David MD
Clinical Journal of Pain: Post Acceptance: April 26, 2017
doi: 10.1097/AJP.0000000000000503
Original Article: PDF Only

Objectives: To evaluate whether orexin receptor antagonism with filorexant provides pain relief in patients with painful diabetic neuropathy (PDN).

Methods: In this double-blind, placebo-controlled, enriched-enrollment, randomized-withdrawal proof-of-concept study, patients with PDN (aged 18-75 y) entered a 2-week, single-blind active run-in period with filorexant 10 mg nightly, before randomization 1:1 to placebo or filorexant in a 2-week, double-blind treatment period. The primary efficacy endpoint was time to efficacy failure among "primary responders" (>=30% decrease in evening pain intensity during the run-in). Secondary endpoints were time to efficacy failure among "all responders" (>=20% decrease in evening pain intensity during the run-in) and mean change from baseline in evening pain intensity throughout last 3 days of the double-blind period.

Results: Of 182 patients treated during the run-in, 170 were randomized in the double-blind period, including 65 primary responders and 88 responders. There was no significant difference in proportion of patients with efficacy failure during the double-blind period with filorexant versus placebo among primary (24.3% vs. 32.1% [P=0.411]) or all (34.0% vs. 43.9% [nominal P=0.302]) responders or in mean change from baseline in evening pain intensity scores (estimated treatment difference: -0.587 [P=0.269], primary; -0.687 [P=0.108], all). Adverse events (AEs) were reported by 24.7% of patients during the run-in. A higher proportion of patients treated with filorexant versus placebo reported AEs during the double-blind period (23.9% vs. 13.4%).

Discussion: These data do not provide evidence for the efficacy of nightly filorexant for the treatment of PDN.

Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.